In short
Clinical trials are studying Idarubicin in different cancer settings, mainly acute myeloid leukemia and some other blood or liver cancer studies. These trials look at safety, effectiveness, and treatment results in specific patient groups such as adults, older adults, and children.
Key points
- Clinical trials investigating Idarubicin are mainly studying acute myeloid leukemia, with one study in older adults with acute lymphoblastic leukemia and one in intermediate stage liver cancer. The trials range from Phase 1 to Phase 4, so they include early safety and dose work as well as larger comparison studies. Some trials focus on newly diagnosed patients, while others focus on specific groups such as children with FLT3-mutated disease or adults with intermediate or adverse risk AML. The main outcomes include complete remission, minimal residual disease, safety, tolerability, event-free survival, overall survival, and time to progression. Idarubicin is being tested as part of combination treatment plans rather than alone. The studies are authorised and include both smaller early trials and larger randomized trials.
Clinical trials overview
The trial data show that Idarubicin is being studied in interventional clinical trials, which means researchers are giving planned treatments and measuring the results.
Most of the studies focus on acute myeloid leukemia (AML), and the trials also include one study in older adults with Philadelphia-negative B-cell precursor acute lymphoblastic leukemia and one study in intermediate stage hepatocellular carcinoma.
Studies in acute myeloid leukemia
Several trials study Idarubicin in AML, including newly diagnosed disease and specific risk groups such as intermediate or adverse risk AML and FLT3-mutated AML.
One Phase 2 study compares CPX-351 with intensive chemotherapy in patients with de novo intermediate or adverse risk AML, and the main goal is to compare the share of patients who reach a deep remission after the first induction course.
In this study, the trial uses a minimal residual disease (MRD) measure in the bone marrow, which checks for very small amounts of disease after treatment.
Another Phase 1 study tests Venetoclax with Fludarabine, Cytarabine, and Idarubicin in newly diagnosed AML that is not low risk, and it looks at both safety and how often patients reach complete remission.
A Phase 1b study evaluates Bleximenib with AML-directed therapies in AML with KMT2A or NPM1 alterations, and its main focus is safety, side effects, and dose selection.
These AML trials show that Idarubicin is being used in combination treatment plans rather than as a single study drug.
Other patient groups and cancer types
One Phase 2 global study includes newly diagnosed pediatric patients with FLT3-mutated AML and tests midostaurin together with chemotherapy that includes Idarubicin.
This pediatric study measures safety, tolerability, and treatment interruptions or dose changes, which helps show how well children can stay on therapy.
Another trial studies older adults with newly diagnosed Philadelphia-negative B-cell precursor acute lymphoblastic leukemia and compares blinatumomab alternating with low-intensity chemotherapy against standard chemotherapy.
In that older-adult study, Idarubicin appears in the standard-of-care chemotherapy arm, and the trial measures event-free survival and overall survival in the Phase 3 part.
There is also a Phase 4 study in intermediate stage hepatocellular carcinoma, where Idarubicin is part of the treatment used in the trial’s liver cancer procedure-based approach.
Trial phases and main endpoints
The trial phases range from Phase 1 to Phase 4, which means the research includes early studies, mid-stage studies, and larger comparison studies.
Common endpoints include complete remission (CR), complete remission with incomplete blood recovery (CRi), and CR with partial blood count recovery (CRp), which are ways to describe how well the cancer responds to treatment.
Other important endpoints are safety, tolerability, adverse events, dose interruptions, dose reductions, and treatment stopping because of the study drug.
For the larger studies, the endpoints also include event-free survival, overall survival, and time to progression, which help show how long patients stay well and how long the disease remains controlled.
Who the trials are designed for
The trial data show several target groups: adults with newly diagnosed AML, patients with intermediate or adverse risk AML, children with FLT3-mutated AML, older adults with Philadelphia-negative B-cell precursor ALL, and people with intermediate stage hepatocellular carcinoma.
Some studies are very specific, such as the AML trial for KMT2A or NPM1 alterations, while others are broader and include newly diagnosed patients who are not low risk.
The enrollment numbers are different across studies, from small early trials with 22 participants to larger trials with 307 participants, showing a mix of early and more advanced research.
Key takeaways from the trial data
Idarubicin is being studied mainly as part of combination treatment plans for blood cancers, especially AML.
The studies aim to learn whether these combinations improve remission rates, reduce measurable disease, and support better survival outcomes while keeping treatment safe and manageable.
Because the trials are in different phases and include different patient groups, they give a broad view of how Idarubicin is being tested in modern cancer research.